Hong Kong · Delayed Price · Currency is HKD Shanghai Bio-heart Biological Technology Company Description
Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China.
The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis.
It is also involved in local administration and manufacturing services. The company was founded in 2014 and is headquartered in Shanghai, China.
| Country | China |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Li Wang |
Contact Details
Address: Building 4 Shanghai China | |
| Phone | 86 21 6879 8511 |
| Website | bio-heart.com |
Stock Details
| Ticker Symbol | 2185 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100004JH3 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Li Wang | Executive Chairman of the Board, Chief Executive Officer and GM |
| Yunqing Wang | Chief Financial Officer, Joint Company Secretary and Executive Director |
| Peili Wang | Financial Manager and Executive Director |
| Tao Cai | Chairperson of the Board of Supervisors and Head of Technology |
| Dr. Bradley Stewart Hubbard D.V.M. | Chief Medical Officer |
| Siu Ying Kwok | Joint Company Secretary |